|Articles|January 4, 2018

Exposure to Drugs & Violence in Adolescence May Increase Risk for HIV in Adulthood

A new study suggests that exposure to drugs and violence in adolescence may increase the risk of HIV infection in adulthood.

New research coming in from the University of Michigan suggests that those who have been exposed to certain types of mental and physical stress during adolescence may experience a higher incidence of HIV as adults.

In a longitudinal study, which spanned a total of 18 years (September 1994 to May 2013), investigators from the University of Michigan analyzed the effects that exposure to illicit drug use and violence had on adolescents in later adulthood.

The findings suggest that exposure to these factors during this developmental period could substantially increase the likelihood of these individuals practicing risky behaviors that increase the risk of acquiring HIV infection.

The study involved 850 Michigan students who were mostly of African-American descent. Respondents were questioned regarding their sexual activity and behavior, perceived mental health, and whether they were either victims or witnesses of violence. Respondents were also asked about their social conditions, such as families, peers, and other community factors. Starting at about age 15, participants were assessed a total of 6 times during the study until they reached 32 years of age.

Researchers discovered young adults exposed to these risk factors also engaged in the type of sexual behavior that could increase the chance of contracting an HIV infection more frequently — significant differences occurred depending on whether or not respondents reported a greater or lesser degree of exposure.

According to the study’s findings; 1 out of 4 respondents who experienced a higher frequency of co-occurring mental and social risk factors in adolescence were also more likely to report having unprotected intercourse with recent partners, as well as sexual intercourse with partners they recently met in adulthood.

Furthermore, those respondents were also more likely to use illegal drugs prior to sexual intercourse and have 4 or more sexual partners. Therefore, these high-frequency respondents were more vulnerable to HIV infection than those who reported a lower frequency of violence, drug use, and mental distress.

The impact of these experiences was evidenced by some of these HIV-risky behaviors (initially observed in adolescence), also extending into middle adulthood.

"Our findings support the notion that the increasing frequency of psychosocial risk factors experienced during adolescence may have effects on HIV risk behaviors decades later," lead study author David Córdova, PhD, assistant professor, social work, University of Michigan, stated in a recent press release.

“Given that this was a secondary data analysis, we are limited by the data collected,” Dr. Córdova told MD Magazine when asked about the effect of exposure on the incidence of homosexual and bisexual behavior that increases the risk of contracting HIV. “Unfortunately, data on sexual abuse and bisexual/same-sex behaviors were not collected, and these may be important factors to examine in future research.”

Although evidence suggests that exposure to drugs and violence in adolescence increases the likelihood of behaviors that increase the incidence of HIV infection, there is a substantial caveat.

Dr. Córdova states that since the study’s respondents were mostly African-American, the findings may not be applicable to other adolescent populations.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.